Show simple item record

dc.contributor.authorCederquist, Carly T.
dc.contributor.authorLentucci, Claudia
dc.contributor.authorCalejman, Camila Martinez
dc.contributor.authorHayashi, Vanessa
dc.contributor.authorOrofino, Joseph
dc.contributor.authorGuertin, David A.
dc.contributor.authorFried, Susan K.
dc.contributor.authorLee, Mi-Jeong
dc.contributor.authorCardamone, M. Dafne
dc.contributor.authorPerissi, Valentina
dc.date2022-08-11T08:09:47.000
dc.date.accessioned2022-08-23T16:43:24Z
dc.date.available2022-08-23T16:43:24Z
dc.date.issued2017-01-01
dc.date.submitted2017-06-09
dc.identifier.citationMol Metab. 2016 Oct 31;6(1):125-137. eCollection 2017 Jan. <a href="https://doi.org/10.1016/j.molmet.2016.10.007">Link to article on publisher's site</a>
dc.identifier.issn2212-8778 (Linking)
dc.identifier.doi10.1016/j.molmet.2016.10.007
dc.identifier.pmid28123943
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40285
dc.description.abstractOBJECTIVE: Insulin signaling plays a unique role in the regulation of energy homeostasis and the impairment of insulin action is associated with altered lipid metabolism, obesity, and Type 2 Diabetes. The main aim of this study was to provide further insight into the regulatory mechanisms governing the insulin signaling pathway by investigating the role of non-proteolytic ubiquitination in insulin-mediated activation of AKT. METHODS: The molecular mechanism of AKT regulation through ubiquitination is first dissected in vitro in 3T3-L1 preadipocytes and then validated in vivo using mice with adipo-specific deletion of GPS2, an endogenous inhibitor of Ubc13 activity (GPS2-AKO mice). RESULTS: Our results indicate that K63 ubiquitination is a critical component of AKT activation in the insulin signaling pathway and that counter-regulation of this step is provided by GPS2 preventing AKT ubiquitination through inhibition of Ubc13 enzymatic activity. Removal of this negative checkpoint, through GPS2 downregulation or genetic deletion, results in sustained activation of insulin signaling both in vitro and in vivo. As a result, the balance between lipid accumulation and utilization is shifted toward storage in the adipose tissue and GPS2-AKO mice become obese under normal laboratory chow diet. However, the adipose tissue of GPS2-AKO mice is not inflamed, the levels of circulating adiponectin are elevated, and systemic insulin sensitivity is overall improved. CONCLUSIONS: Our findings characterize a novel layer of regulation of the insulin signaling pathway based on non-proteolytic ubiquitination of AKT and define GPS2 as a previously unrecognized component of the insulin signaling cascade. In accordance with this role, we have shown that GPS2 presence in adipocytes modulates systemic metabolism by restricting the activation of insulin signaling during the fasted state, whereas in absence of GPS2, the adipose tissue is more efficient at lipid storage, and obesity becomes uncoupled from inflammation and insulin resistance.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28123943&dopt=Abstract">Link to Article in PubMed</a>
dc.rights© 2016 The Authors.
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAKT
dc.subjectAdipose tissue
dc.subjectGPS2
dc.subjectInsulin
dc.subjectObesity
dc.subjectUbiquitin
dc.subjectBiochemistry
dc.subjectCellular and Molecular Physiology
dc.subjectMolecular Biology
dc.titleSystemic insulin sensitivity is regulated by GPS2 inhibition of AKT ubiquitination and activation in adipose tissue
dc.typeJournal Article
dc.source.journaltitleMolecular metabolism
dc.source.volume6
dc.source.issue1
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4091&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3086
dc.identifier.contextkey10275069
refterms.dateFOA2022-08-23T16:43:24Z
html.description.abstract<p>OBJECTIVE: Insulin signaling plays a unique role in the regulation of energy homeostasis and the impairment of insulin action is associated with altered lipid metabolism, obesity, and Type 2 Diabetes. The main aim of this study was to provide further insight into the regulatory mechanisms governing the insulin signaling pathway by investigating the role of non-proteolytic ubiquitination in insulin-mediated activation of AKT.</p> <p>METHODS: The molecular mechanism of AKT regulation through ubiquitination is first dissected in vitro in 3T3-L1 preadipocytes and then validated in vivo using mice with adipo-specific deletion of GPS2, an endogenous inhibitor of Ubc13 activity (GPS2-AKO mice).</p> <p>RESULTS: Our results indicate that K63 ubiquitination is a critical component of AKT activation in the insulin signaling pathway and that counter-regulation of this step is provided by GPS2 preventing AKT ubiquitination through inhibition of Ubc13 enzymatic activity. Removal of this negative checkpoint, through GPS2 downregulation or genetic deletion, results in sustained activation of insulin signaling both in vitro and in vivo. As a result, the balance between lipid accumulation and utilization is shifted toward storage in the adipose tissue and GPS2-AKO mice become obese under normal laboratory chow diet. However, the adipose tissue of GPS2-AKO mice is not inflamed, the levels of circulating adiponectin are elevated, and systemic insulin sensitivity is overall improved.</p> <p>CONCLUSIONS: Our findings characterize a novel layer of regulation of the insulin signaling pathway based on non-proteolytic ubiquitination of AKT and define GPS2 as a previously unrecognized component of the insulin signaling cascade. In accordance with this role, we have shown that GPS2 presence in adipocytes modulates systemic metabolism by restricting the activation of insulin signaling during the fasted state, whereas in absence of GPS2, the adipose tissue is more efficient at lipid storage, and obesity becomes uncoupled from inflammation and insulin resistance.</p>
dc.identifier.submissionpathoapubs/3086
dc.contributor.departmentUMass Metabolic Network
dc.contributor.departmentProgram in Molecular Medicine
dc.source.pages125-137


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
447547547.pdf
Size:
1.793Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© 2016 The Authors.
Except where otherwise noted, this item's license is described as © 2016 The Authors.